Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 20, 2018
Pharmacy Choice - News - Generic Drugs - September 20, 2018

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 64     Next >>     Go To Page:

9/20/18 - CBO Issues Cost Estimate for Creating and Restoring Equal Access to Equivalent Samples Act
The Congressional Budget Office issued the following cost estimate:. As reported by the Senate Committee on the Judiciary on June 21, 2018. CBO and the staff of the Joint Committee on Taxation estimate that implementing S. 974 would:.
9/19/18 - 4 Pharmaceutical Market Report Bundle 2018: Monoclonal Antibodies Trends, Biopharmaceutical CMO Markets, Single-Use Upstream Bioprocessing Markets & The World Market for Biosimilars
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager. Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./ CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call...
9/19/18 - Allergan buys Bonti and its Botox successor, as biosimilar looms [Tehran Times (Iran)]
Allergan has bought the privately-held biotech Bonti, which has been developing a fast-acting, short duration replacement alternative to Botox ahead of potentially cheaper competition from a biosimilar next year. Allergan will acquire California- based Bonti for an upfront payment of $195 million and additional potential commercial milestone...
9/19/18 - Global Biosimilars Strategic Business Report 2018
The "Biosimilars- Global Strategic Business Report" report has been added to ResearchAndMarkets.com' s offering. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.
9/19/18 - Global Biosimilars Strategic Markets Report 2018-2024 - Patent Expiry of Major Biopharmaceutical Drugs Leads Way for Biosimilars
The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Reddy's Laboratories Ltd. Eli Lilly and Company Fresenius Kabi Intas Pharmaceuticals Ltd. Mylan N.V. Pfizer, Inc. Samsung Bioepis Co., Ltd. Sandoz International GmbH STADA Arzneimittel AG Teva Pharmaceutical Industries Ltd.. NOTEWORTHY MARKET TRENDS,
9/19/18 - Global Biosimilars Strategic Markets Report 2018-2024 - Rituximab Biosimilars to Proliferate the Market
The "Biosimilars- Global Strategic Business Report" report has been added to ResearchAndMarkets.com' s offering. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. NOTEWORTHY MARKET TRENDS, GROWTH DRIVERS& ISSUES Slew of Product Approvals Scale Up Market Revenues Biosimilar Approvals in Europe Biosi
9/19/18 - Global Parkinson's Disease Drugs Market 2018-2023: Recent Drug Approvals are Driving Growth
In January 2015, the US FDA approved an extended release formulation of levodopa/carbidopa. Recently in January 2018, Adamas Pharmaceuticals Inc. has launched Gocovri for the treatment of dyskinesia in people with Parkinson's, who are taking levodopa. -Generic Competition to Key Therapies- Restraining the Market.
9/19/18 - Global Parkinson's Disease Drugs Market 2018-2023: Recent Drug Approvals are Driving Growth - ResearchAndMarkets.com
In January 2015, the US FDA approved an extended release formulation of levodopa/carbidopa. Recently in January 2018, Adamas Pharmaceuticals Inc. has launched Gocovri for the treatment of dyskinesia in people with Parkinson's, who are taking levodopa. Key Highlights Generic Competition to Key Therapies- Restraining the Market Europe Holds the Large
9/19/18 - Health and Human Services Department; Food and Drug Administration (FDA) (F.R. Page 42125) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Pediatric Advisory Committee. AGENDA: Agenda includes: discuss the following Center for Drug Evaluation and Research products, INTUNIV and LEXAPRO; overview of the FDA Adverse Event Reporting System and lack of efficacy; generic drug approval process; d
9/19/18 - MELINTA THERAPEUTICS, INC. /NEW/ FILES (8-K) Disclosing Change in Directors or Principal Officers, Financial Statements and Exhibits
Mr. Milligan, age 51, joined the Company as of September 17, 2018. Prior to joining the Company, Mr. Milligan served as Chief Financial Officer of G&W Laboratories, Inc., a privately held generic pharmaceutical company where he had oversight and leadership of all financial aspects of the company, including financial planning and analysis, accountin
9/19/18 - Pharmaceutical Market Research Bundle 2018: Monoclonal Antibody Markets, CMOs, Bioprocessing Markets, Biosimilar Drug Markets Reports
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager. CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Cal
9/19/18 - The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering
Boston Scientific Corporation Cara Therapeutics Inc Champions Oncology Inc Chiasma Inc Emergent Biosolutions Inc Genomic Health, Inc. Ligand Pharmaceuticals Inc. Pfizer Inc. Shire PLC Viking Therapeutics Inc Zimmer Biomet Holdings Inc Down In The Dumps. Altimmune Inc Arsanis Inc Atossa Genetics Inc Bio-Path Holdings Inc Constellation...
9/18/18 - Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis
MISSISSAUGA, ON, Sept. 18, 2018/ CNW/- Cipher Pharmaceuticals Inc. today announced it has acquired the exclusive Canadian rights to commercialize, promote, sell and distribute MOB-015 from Moberg Pharma. In Canada, according to IMS, the total prescription market for Onychomycosis was $58 M CDN in 2017, 72% of which were topical drugs, growing stead
9/18/18 - Elite Pharmaceuticals Files ANDA for Codeine and Acetaminophen Combo
Elite Pharmaceuticals, Inc. a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has filed an Abbreviated New Drug Application with the US Food and Drug Administration for a generic version of Tylenol with Codeine 300 mg/7. 5 mg, 300 mg/15mg, 300 mg/30mg, and 300 mg/60mg tabl
9/18/18 - ELITE PHARMACEUTICALS INC /NV/ FILES (8-K) Disclosing Regulation FD Disclosure, Financial Statements and Exhibits
Item 7.01 Regulation FD Disclosure. On September 18, 2018, in a press release, Elite Pharmaceuticals, Inc., or Elite, reported that it has filed an Abbreviated New Drug Application with the US Food and Drug Administration for a generic version of Tylenol with Codeine 300 mg/7. 5 mg, 300 mg/15mg, 300 mg/30mg and 300 mg/60mg tablets. 99.1 Press Re
9/18/18 - GLENMARK PHARMA GETS USFDA NOD FOR VAGIFEM
The US Food and Drug Administration has given its final approval for generic version of VAGIFEM of Nordisk, indicated for the treatment of menopause symptoms, manufactured by Glenmark Pharmaceuticals.
9/18/18 - Sun Pharma and SPARC Announce US FDA Approval of XELPROS to Treat Open-angle Glaucoma or Ocular Hypertension
MUMBAI- Sun Pharmaceutical Industries Ltd. and Sun Pharma Advanced Research Company Ltd. today announced U.S. Food and Drug Administration approval for the New Drug Application of XELPROSTM 0.005% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. 'As the only BAK-free version of latanopr
9/18/18 - Sun wins approval of glaucoma drug and its once-troubled Halol plant to produce it [Syrian Arab News Agency]
Indias Sun Pharmaceuticals, which is working hard to shift its focus from generic to novel and specialty drugs, has won FDA approval of a new treatment for glaucoma. The drug will be made at Suns once-troubled Halol plant, indicating that problems there have been resolved after nearly four years. As the only BAK-free version of latanoprost, XELPROS
9/18/18 - Vibcare Pharma Pvt. Ltd Is Providing Third Party Pharma Manufacturing Services to Pharmaceutical Businesses
Panchkula, Haryana 09/17/2018 Vibcare Pharma is a pharmaceutical company in India striving to increase access to quality healthcare, marketing and producing affordable generic drugs in CIS, Domestic, South Asia and African markets. The company formulates and manufactures medications using concerted efforts and focus on ensuring there is a bet
9/18/18 - Vibcare Pharma Pvt. Ltd. Producing and Marketing Affordable Generic Pharmaceutical Drugs
Vibcare Pharma, a leading PCD pharma company operating in India and a provider of PCD pharma franchise, is offering cost-effective generic drugs in domestic, as well as international markets.
9/17/18 - Costs of generic drugs and outpatient services targeted [Sudan Tribune]
The government wants to cap prices for generic drugs as part of a package of measures to reduce rising health costs in Switzerland. Interior Minister Alain Berset, whose portfolio includes health issues, on Friday presented plans to allow health insurers, health service providers and cantonal authorities to launch pilot projects to test innovative.
9/17/18 - Health and Human Services Department; Food and Drug Administration (F.R. Page 46172) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Oncologic Drugs Advisory Committee to discuss biologics license application 761088 for CT-P10, a proposed biosimilar to Genentech, Inc.' s RITUXAN, submitted by Celltrion, Inc.. LOCATION: FDA White Oak Campus, 10903 New Hampshire Avenue, Building 31 Con
9/17/18 - Health and Human Services Department; Food and Drug Administration (FDA) (F.R. Page 42125) - Meeting
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting of the Pediatric Advisory Committee. AGENDA: Agenda includes: discuss the following Center for Drug Evaluation and Research products, INTUNIV and LEXAPRO; overview of the FDA Adverse Event Reporting System and lack of efficacy; generic drug approval process; d
9/17/18 - Intellipharmaceutics Announces One-for-10 Reverse Stock Split
TORONTO- Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid-dosage drugs, announced today that it implemented a one-for-ten share consolidation. At a special meeting of the Company's shareholders held...
9/17/18 - Mid-Afternoon Market Update: Dow Falls Over 50 Points; Select Income REIT Shares Spike Higher
Meanwhile, top gainers in the sector included Select Income REIT up 13 percent, and Farmland Partners Inc. up 5 percent. Teva Pharmaceutical Industries Ltd ADR has struggled amid sagging sales of its blockbuster multiple sclerosis treatment Capaxone due to a generic launch in 2017 and its debt burden following the purchase of Allergan plc' s gene
Articles(s): 1 - 25 of 64     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415